Blood Patents (Class 530/829)
  • Patent number: 4902782
    Abstract: Basic Fibroblast Growth Factor (FGF) is substantially purified by the employment of affinity chromatography using heparin-linked support material. Described is a simplified three step procedure for extracting basic FGF from either mammalian brain or mammalian pituitary tissue. Salt precipitation, e.g., with ammonium sulfate is used to provide a partially purified precipitate that is then subjected to ion-exchange chromatography, e.g., using a Carboxymethyl-Sephadex column. Substantially pure basic FGF fractions are then obtained by fractionating the further partially purified fractions using affinity chromatography on a heparin-linked support e.g., Heparin-Sepharose.
    Type: Grant
    Filed: November 7, 1988
    Date of Patent: February 20, 1990
    Assignee: The Salk Institute for Biological Studies
    Inventors: Denis Gospodarowicz, Andrew Baird, Peter Bohlen
  • Patent number: 4886876
    Abstract: Active factor VIII:C coagulant polypeptides identified by partial amino acid sequences are disclosed.
    Type: Grant
    Filed: April 13, 1987
    Date of Patent: December 12, 1989
    Assignee: Scripps Clinic and Research Foundation
    Inventors: Theodore S. Zimmerman, Carol A. Fulcher
  • Patent number: 4883784
    Abstract: The administration of Factor I and/or Factor H to a mammal has been found to alleviate or prevent such autoimmune diseases as systemic lupus erythematosus, rheumatoid arthritis and glomerulonephritis.
    Type: Grant
    Filed: April 13, 1988
    Date of Patent: November 28, 1989
    Assignee: Sankyo Company Limited
    Inventor: Isao Kaneko
  • Patent number: 4870163
    Abstract: Human TNF(LuKII) having a specific activity of at least 1.5.times.10.sup.5 units per milligram of total protein is produced by contacting a TNF-containing protein composition, which has been harvested from human cell lines of hematopoietic origin or recombinant origin, in separate adsorption stages with glass beads, lentil lectin bound to Sepharose, and procion red agarose, thereby selectively to adsorb TNF in each stage, while leaving some impurities unadsorbed, each contact stage being followed by contact of the adsorbent with an eluant thereby to obtain a solution of more highly purified TNF after each stage. The purified human TNF(LuKII) is used to produce monoclonal antibodies against TNF(LuKII) and such antibodies can be used to assay samples for the presence of TNF(LuKII).
    Type: Grant
    Filed: August 29, 1985
    Date of Patent: September 26, 1989
    Assignees: New York Blood Center, Inc., Sloan-Kettering Institute for Cancer Research
    Inventors: Berish Y. Rubin, Sylvia L. Anderson, Susan A. Sullivan, Lloyd J. Old, Barbara D. Williamson, Elizabeth C. Richards
  • Patent number: 4867976
    Abstract: A method for treatment of acquired immuno-deficiency syndrome (AIDS) which comprises administering a therapeutically effective amount of liposomes containing a toxin which specifically inhibits the protein synthesis in cells to a patient with AIDS.
    Type: Grant
    Filed: July 2, 1987
    Date of Patent: September 19, 1989
    Assignee: Sumitomo Chemical Company, Limited
    Inventors: Shigeharu Ueda, Kazuyoshi Ikuta, Shiro Kato, Tsuyoshi Uchida
  • Patent number: 4863897
    Abstract: This invention relates to cosmetic, health- and body-preserving compositions of high biological value, optimizing the biological processes occurring in the skin cells and providing the most preferable function of the enzyme system of the cells connected with the age of the organism.The compositions of the invention contain in addition to the commonly used carrier and additive and/or filling materials and active ingredients, mineral waters of a native condition, medicinal waters and/or the mixtures thereof and/or the mixtures thereof with fermented or non-fermented plant juices and/or optionally inorganic materials playing the role of trace elements in the living organism as well as proteins.
    Type: Grant
    Filed: August 3, 1987
    Date of Patent: September 5, 1989
    Assignee: Caola Kozmetikai es Haztartasvegyipari Vallalat
    Inventors: Laszlo Dede, Maria Dede nee Pal, Laszlo Bogdany, Olga Bogdany nee Forgacs
  • Patent number: 4857635
    Abstract: Polypeptides have been discovered which exhibit high specific VIII:C coagulant activity. Monoclonal antibodies to the polypeptides are also disclosed.
    Type: Grant
    Filed: September 20, 1985
    Date of Patent: August 15, 1989
    Assignee: Scripps Clinic and Research Foundation
    Inventors: Theodore S. Zimmerman, Carol A. Fulcher
  • Patent number: 4853220
    Abstract: The invention relates to Tetranectin, a new protein isolated from blood. Its structure comprises four polypeptide chains having the formula shown in the attached drawing.Tetranectin plays a role in the hemostatic system and, therefore, may be used as an agent for regulation of hemostasis.Further, the invention relates to a process for preparing Tetranectin in which Tetranectin is isolated e.g. from blood or blood fractions, cells or genetically engineered organisms.Finally the invention relates to antiserum or antibodies against Tetranectin, to immunological detection and assay methods wherein said antiserum or antibodies are used as immunological reagent, and to pharmaceutical compositions containing Tetranectin or antibodies against Tetranectin.
    Type: Grant
    Filed: June 10, 1986
    Date of Patent: August 1, 1989
    Assignee: Nederlandse Centrale Organisatie Voor Toegerastnatuurwete Nschappelijk Onderzoek
    Inventors: Inge D. Clemmensen, Cornelis Kluft
  • Patent number: 4835260
    Abstract: A new improved glycoprotein having erythropoietin-type activity is disclosed. The substrate is characterized by amino acid sequence substantially identical to the amino acid sequence of native human erythropoietin wherein the methionine-54 is replaced with leucine. DNA encoding for the EPO-substance and expression vectors incorporating the same are disclosed. Therapeutic compositions and methods for treatment of anemic conditions are described.
    Type: Grant
    Filed: March 20, 1987
    Date of Patent: May 30, 1989
    Assignee: Genetics Institute, Inc.
    Inventor: Charles B. Shoemaker
  • Patent number: 4822776
    Abstract: A mediator substance exhibiting inhibitory effect upon anabolic enzyme activity in mammals, is prepared by a method comprising gathering a sample of macrophage cells from a mammal, incubating a portion of the macrophage cells with a stimulating mateThis invention was made in the course of a grant from the National Institutes of Health.
    Type: Grant
    Filed: October 29, 1985
    Date of Patent: April 18, 1989
    Assignee: The Rockefeller University
    Inventors: Anthony Cerami, Masanobu Kawakami
  • Patent number: 4820805
    Abstract: A mammalian blood protein-containing composition such as whole blood, plasma, serum, plasma concentrate, cryoprecipitate, cryosupernatant, plasma fractionation precipitate or plasma fractionation supernatant substantially free of hepatitis and other lipid coated viruses with the yield of protein activity to total protein being at least 80% is disclosed. The protein-containing composition is contacted with di- or trialkylphosphate, preferably a mixture of trialkylphosphate and detergent, usually followed by removal of the di- or trialkylphosphate.
    Type: Grant
    Filed: April 22, 1985
    Date of Patent: April 11, 1989
    Assignee: New York Blood Center, Inc.
    Inventors: Alexander R. Neurath, Bernard Horowitz
  • Patent number: 4783525
    Abstract: To diagnose diseases in patients, a protein complex, RhC, is prepared from horse serum by precipitating a white powder from the serum at a pH of 5.5 and processing to remove lipids at a pH of 8.2 using Tris-HCl as the buffer. It includes two components associated together to provide a molecular weight of 280,000 and having characteristics of a rheumatoid factor and a Clq-like subcomponent of the complement. The protein complex is incubated with human serum or plasma and then precipitated by dialysis against a high pH buffer (0.05 M Tris-HCl pH 8.2). When precipitated, it co-precipitates the immune complexes from the human blood serum without substantial monomeric immunoglobulin to quantitatively isolate immune complexes from serum. Immunological assays then determine how much immune complex and what kind were in the serum.
    Type: Grant
    Filed: January 9, 1986
    Date of Patent: November 8, 1988
    Assignee: The Board of Regents of the University of Nebraska
    Inventor: Thomas L. McDonald
  • Patent number: 4780529
    Abstract: An endotoxin inactivator is isolated from human plasma by anion exchange (DEAE-Sephadex), dye-affinity (Cibracron Blue-Sepharose), and adsorption (on hydroxyapatite) chromatography. The endotoxin inactivator, isolated in essentially pure form, may be used to depyrogenate clinical blood products.
    Type: Grant
    Filed: June 16, 1987
    Date of Patent: October 25, 1988
    Assignee: Biotech Research Laboratories, Inc.
    Inventor: Yu-Lee Hao
  • Patent number: 4748120
    Abstract: Biological compositions are freed of functional polynucleotides by treatment of the biological composition with psoralen derivatives under irradiation conditions in which the proteins retain their original physiological activities and any polynucleotide present is rendered inactive.
    Type: Grant
    Filed: October 20, 1986
    Date of Patent: May 31, 1988
    Assignee: Diamond Scientific Co.
    Inventor: Gary P. Wiesehahn
  • Patent number: 4725669
    Abstract: A first glycoprotein having a molecular weight of approximately 120,000 daltons in the H9/HTLV-III cell line, of which approximately 90,000 daltons is the unglycosylated moiety, is obtained from cells infected with human T-cell leukemia virus, type III. A second glycoprotein having a molecular weight of aproximately 160,000 daltons is also obtained from such cells, of which approximately 90,000 daltons is the unglycosylated moiety and is substantially identical to the unglycosylated moiety of the first glycoprotein.The presence, in a biological specimen, of either of these glycoproteins or of the unglycosylated moiety is indicative of the presence of cells infected by human T-cell leukemia virus. An assay for the glycoprotein or its unglycosylated moiety is a useful diagnostic procedure for determining such infection in biological specimens.
    Type: Grant
    Filed: November 9, 1984
    Date of Patent: February 16, 1988
    Assignee: President and Fellows of Harvard College
    Inventors: Myron E. Essex, Tun-Hou Lee
  • Patent number: 4722998
    Abstract: The present invention is directed to a method of producing growth factors for mammalian cells. More particularly, the method of the present invention comprises isolating mammalian inducer T-lymphocytes, and stimulating growth factor production by contacting these inducer lymphocytes with an antigen or a mitogen. The resulting growth factors are then separated from the material produced by the stimulated lymphocytes.
    Type: Grant
    Filed: June 5, 1986
    Date of Patent: February 2, 1988
    Assignee: Dana Farber Cancer Institute
    Inventors: Harvey I. Cantor, Gary Nabel
  • Patent number: 4677194
    Abstract: An endotoxin inactivator is isolated from human plasma by anion exchange (DEAE-Sephadex), dye-affinity (Cibracron Blue-Sepharose), and adsorption (on hydroxyapatite) chromatography. The endotoxin inactivator, isolated in essentially pure form, may be used to depyrogenate clinical blood products.
    Type: Grant
    Filed: August 9, 1985
    Date of Patent: June 30, 1987
    Assignee: Biotech Research Laboratories, Inc.
    Inventor: Yu-Lee Hao
  • Patent number: 4656251
    Abstract: A method for the rapid separation of Dirofilaria immitis immune complexes in a sample of blood or bodily fluid from an animal infected with Dirofilaria immitis preparatory to assaying for the presence of circulating parasite antigens of Dirofilaria immitis involves the steps of (a) lowering the pH of the sample to below 3.0 to effect the separation of circulating parasite antigens of Dirofilaria immitis from antibodies therefor in the sample; (b) heating the sample to a temperature within the range of approximately 56.degree. C. to 90.degree. C. for a sufficient period of time to denature the separated antibodies; and (c) increasing the pH of the resulting sample to within the range of approximately 7 to 8 to produce a sample which may be assayed for the presence of circulating parasite antigens of Dirofilaria immitis without interference from the separated antibodies.
    Type: Grant
    Filed: January 28, 1985
    Date of Patent: April 7, 1987
    Assignee: Mallinckrodt, Inc.
    Inventor: Larry D. Mosier
  • Patent number: 4647654
    Abstract: Monoclonal antibodies specific for the glucosylated N-terminal peptide residue in Hb A.sub.1c, a method for producing such antibodies, hybridoma cell lines secreting such antibodies and a method for their production, and immunoassay methods and reagent systems using such antibodies for the determination of Hb A.sub.1c in human blood samples. The monoclonal antibodies are secreted by hybridomas obtained from the fusion of a myeloma cell and a lymphocyte which has been taken from an animal, preferably a mouse, immunized with a synthetic peptide immunogen and which produces antibody specific for the glucosylated N-terminal peptide residue in Hb A.sub.1c. The synthetic peptide immunogen comprises an N-terminal glucosylated peptide residue having at least 2 amino acid units corresponding to the N-terminus of the beta-subunit of human hemoglobin and an immunogenic carrier to which the glucosylated peptide residue is linked.
    Type: Grant
    Filed: August 8, 1985
    Date of Patent: March 3, 1987
    Assignee: Molecular Diagnostics, Inc.
    Inventors: William J. Knowles, Vincent T. Marchesi, Wallace Haigh
  • Patent number: 4632980
    Abstract: Blood and proteinaceous blood products employed for their physiological and/or immunological properties are free of viable enveloped viruses by treatment with low levels of ozone, levels at which substantially all of the physiological and/or immunological activity is retained.
    Type: Grant
    Filed: April 3, 1985
    Date of Patent: December 30, 1986
    Assignee: Immunologics
    Inventors: Yuan C. Zee, David C. Bolton
  • Patent number: 4616079
    Abstract: A high pressure liquid chromatography process is described for the extraction of materials that nonspecifically amplify the immune response to antigens to which the subject was previously or is concomitantly exposed. The materials are also described, as are methods and compositions for the use thereof in connection with hypoimmune conditions.
    Type: Grant
    Filed: August 24, 1984
    Date of Patent: October 7, 1986
    Assignee: Imreg, Inc.
    Inventor: A. Arthur Gottlieb